RANDOMISED, CROSSOVER, SIMPLE-BLINDED, BIOEQUIVALENCE CLINICAL TRIAL OF ALMOTRIPTAN 12.5 MG ORODISPERSIBLE TABLETS VERSUS ALMOTRIPTAN 12.5 MG FILM-COATED TABLETS, AFTER A SINGLE ORAL DOSE ADMINISTRATION TO HEALTHY VOLUNTEERS UNDER FASTING
This research is looking at a medicine called almotriptan, which is used to treat migraines. We are comparing two different forms of this medicine: a standard tablet and a new "orodispersible" tablet that dissolves quickly in the mouth. The main goal is to check if these two types of tablets deliver the same amount of medicine into the body and work similarly. This is called a 'bioequivalence' study. Healthy adult volunteers will take one dose of the medicine after not eating for a certain period. The study is important to ensure that if a new tablet form is made available, it will be just as effective as the original.
At a glance
What is this study about?
This study is about a medication called almotriptan, which is commonly used to help people who suffer from migraine headaches. When a new version of an existing medicine is developed, for example, a tablet that dissolves quickly, it's very important to make sure it works just as well as the original version. This study aims to do exactly that by comparing a new fast-dissolving (orodispersible) almotriptan tablet with the standard film-coated almotriptan tablet.
The main purpose is to see if both tablet types deliver the same amount of active medicine into your bloodstream and at a similar speed. This is known as a 'bioequivalence' study. If they are 'bioequivalent', it means they can be used interchangeably, giving patients more options while ensuring they get the same treatment effect. This kind of research is standard practice before new forms of medicines can be approved for wider use.
By taking part, you would be helping us understand how these different tablet forms act in the body. This information is crucial for ensuring that people who need almotriptan for their migraines continue to receive effective treatment, regardless of which tablet type they use. It contributes to making new and potentially more convenient medication options available safely.
Key takeaways
- This study compares two types of migraine tablets.
- It checks if a new fast-dissolving tablet works like the standard one.
- Healthy adult volunteers are needed.
- Participants will take a single dose of each tablet type, on separate occasions.
- All health checks and procedures are aimed at ensuring safety.
- Your participation helps improve choices for migraine sufferers.
Who may be eligible?
This study is looking for healthy adults to take part. To be considered, you need to be at least 18 years old – there's no upper age limit, so older adults can also participate.
Both men and women are welcome to join this study. The most important thing is that you are generally healthy, meaning you don't have any serious ongoing medical conditions that could affect how your body handles the medication being studied.
Before you can take part, doctors will check your health carefully to make sure the study is safe for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Am I at least 18 years old?
- Am I generally healthy with no major ongoing medical conditions?
- Am I able to follow specific instructions, like fasting?
- Am I comfortable with regular blood tests?
- Am I available for multiple clinic visits over a period of time?
What does participation involve?
If you decide to take part, you'll be asked to visit the study clinic on several occasions. During these visits, you will receive a single dose of either the standard almotriptan tablet or the new fast-dissolving one. You will be asked not to eat anything for a specific period before taking the medicine. After taking the tablet, your health will be monitored, and blood samples will be taken regularly over a few hours to measure how the medicine is absorbed by your body.
Because this is a 'crossover' study, at a later date, you will repeat the process, but this time you will receive the other type of tablet (if you had the fast-dissolving one first, you'll get the standard one next, and vice versa). There will be a 'washout' period between these two times, meaning enough time will pass for the first dose to completely leave your body before you take the second dose. The total time for your involvement, including all visits and follow-ups, will be explained to you fully.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is almotriptan used for?
Almotriptan is a medication specifically designed to treat migraine headaches.
What does 'orodispersible' mean?
An 'orodispersible' tablet is designed to dissolve quickly in your mouth without needing water.
Why do I need to fast before taking the medicine?
Fasting helps scientists understand how the medicine is absorbed when there's no food interfering, ensuring consistent results across participants.
What is a 'bioequivalence' study?
It's a study that compares two versions of the same medicine to make sure they work in the body in the same way and are equally effective.
Will I know which tablet I'm taking?
This is a 'simple-blinded' study, meaning you might not know which tablet you're receiving, but the study team will know for safety reasons.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.